Novo Nordisk said on Tuesday (August 8) its obesity drug Wegovy reduced the risk of a major cardiovascular event like a stroke by 20% in overweight or obese people with a history of heart disease, exceeding expectations from a key late-stage trial.
Read more about the study: https://www.reuters.com/business/healthcare-pharmaceuticals/novos-weight-loss-drug-wegovy-cuts-risk-heart-disease-by-20-trial-data-2023-08-08/
#Live #News #Shorts #Livenews #reuters
REUTERS | Your source for breaking news. Go to Reuters.com
Subscribe: http://smarturl.it/reuterssubscribe
Reuters brings you the latest business, finance and breaking news video from around the globe. Our reputation for accuracy and impartiality is unparalleled.
Get the latest news on: https://www.reuters.com/
Follow Reuters on Facebook: https://www.facebook.com/Reuters
Follow Reuters on Twitter: https://twitter.com/Reuters
Follow Reuters on Instagram: https://www.instagram.com/reuters/?hl=en
Read more about the study: https://www.reuters.com/business/healthcare-pharmaceuticals/novos-weight-loss-drug-wegovy-cuts-risk-heart-disease-by-20-trial-data-2023-08-08/
#Live #News #Shorts #Livenews #reuters
REUTERS | Your source for breaking news. Go to Reuters.com
Subscribe: http://smarturl.it/reuterssubscribe
Reuters brings you the latest business, finance and breaking news video from around the globe. Our reputation for accuracy and impartiality is unparalleled.
Get the latest news on: https://www.reuters.com/
Follow Reuters on Facebook: https://www.facebook.com/Reuters
Follow Reuters on Twitter: https://twitter.com/Reuters
Follow Reuters on Instagram: https://www.instagram.com/reuters/?hl=en
Sign in or sign up to post comments.
Be the first to comment